Pasithea Therapeutics Corp. (KTTA)Healthcare | Biotechnology | Miami Beach, United States | NasdaqCM
0.56 USD
+0.01
(0.992%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 0.57 +0.01 (1.446%) ⇧ (Aug. 28, 2026, 6:15 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 4:50 a.m. EDT
The investment case here is fractured by a catastrophic multi-year decline. Over the last three years, the stock has lost 97% of its value, with every single year showing double-digit declines, culminating in a massive 85% drop last year. This relentless downward trajectory suggests the market has thoroughly rejected the company's current business model and prospects, regardless of the glowing 'strong buy' analyst consensus which appears to be based on a single, potentially optimistic view of future clinical data rather than current reality. While insider buying and recent news about tolerable study results offer a glimmer of hope for a potential turnaround, the price action tells a different story: the asset is currently priced at a fraction of its book value because investors see no path to profitability or revenue growth. For a biotech firm burning through cash with negative returns on equity and assets, this deep discount is a warning sign of a value trap, not a bargain. There is no dividend to provide income, and the short-term momentum remains flat to slightly negative, lacking the explosive volume or technical breakout needed to justify a speculative entry at these levels. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.066383 |
| AutoETS | 0.066384 |
| MSTL | 0.072937 |
| AutoTheta | 0.122339 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 0.99 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.204 |
| Excess Kurtosis | -0.85 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 18,712,090 |
| Forward P/E | -1.22 |
| Beta | 0.29 |
| Website | https://www.pasithea.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.3826474 |
| Address1 | 1,111 Lincoln Road |
| Address2 | Suite 500 |
| All Time High | 170.0 |
| All Time Low | 0.281 |
| Ask | 0.7248 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 154,950 |
| Average Daily Volume3 Month | 740,775 |
| Average Volume | 740,775 |
| Average Volume10Days | 154,950 |
| Beta | 0.293 |
| Bid | 0.3948 |
| Bid Size | 2 |
| Book Value | 1.492 |
| City | Miami Beach |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.56 |
| Current Ratio | 26.249 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 0.6043 |
| Day Low | 0.5416 |
| Display Name | Pasithea Therapeutics |
| Earnings Timestamp End | 1,755,374,400 |
| Earnings Timestamp Start | 1,754,942,400 |
| Ebitda | -19,138,316 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 1.408 |
| Enterprise Value | -26,951,692 |
| Eps Current Year | -0.76 |
| Eps Forward | -0.46 |
| Eps Trailing Twelve Months | -1.37 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.49518 |
| Fifty Day Average Change | 0.06481999 |
| Fifty Day Average Change Percent | 0.13090187 |
| Fifty Two Week Change Percent | -38.26474 |
| Fifty Two Week High | 2.06 |
| Fifty Two Week High Change | -1.5 |
| Fifty Two Week High Change Percent | -0.7281554 |
| Fifty Two Week Low | 0.281 |
| Fifty Two Week Low Change | 0.279 |
| Fifty Two Week Low Change Percent | 0.99288267 |
| Fifty Two Week Range | 0.281 - 2.06 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,631,712,600,000 |
| Float Shares | 19,683,115 |
| Forward Eps | -0.46 |
| Forward P E | -1.2173913 |
| Free Cashflow | -12,165,350 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 5 |
| Fullday Change | 0.00550002 |
| Fullday Change Percent | 0.991888 |
| Fullday Price | 0.5681 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01114 |
| Held Percent Institutions | 0.63228 |
| Implied Shares Outstanding | 33,414,448 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-09-15 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,704,153,600 |
| Last Split Factor | 1:20 |
| Long Business Summary | Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida. |
| Long Name | Pasithea Therapeutics Corp. |
| Market | us_market |
| Market Cap | 18,712,090 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_702706441 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -21,291,622 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 19,002,796 |
| Number Of Analyst Opinions | 1 |
| Open | 0.574 |
| Operating Cashflow | -17,781,584 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 786 977 3380 |
| Post Market Change | 0.008099973 |
| Post Market Change Percent | 1.4464238 |
| Post Market Price | 0.5681 |
| Post Market Time | 1,787,955,302 |
| Previous Close | 0.5545 |
| Price Eps Current Year | -0.7368421 |
| Price Hint | 4 |
| Price To Book | 0.37533513 |
| Profit Margins | 0.0 |
| Quick Ratio | 24.845 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.00550002 |
| Regular Market Change Percent | 0.991888 |
| Regular Market Day High | 0.6043 |
| Regular Market Day Low | 0.5416 |
| Regular Market Day Range | 0.5416 - 0.6043 |
| Regular Market Open | 0.574 |
| Regular Market Previous Close | 0.5545 |
| Regular Market Price | 0.56 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 455,386 |
| Return On Assets | -0.36003 |
| Return On Equity | -0.65494 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 33,414,448 |
| Shares Percent Shares Out | 0.0076 |
| Shares Short | 253,936 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 242,873 |
| Short Name | Pasithea Therapeutics Corp. |
| Short Percent Of Float | 0.0077 |
| Short Ratio | 0.84 |
| Source Interval | 15 |
| State | FL |
| Symbol | KTTA |
| Target High Price | 3.0 |
| Target Low Price | 3.0 |
| Target Mean Price | 3.0 |
| Target Median Price | 3.0 |
| Total Cash | 45,663,784 |
| Total Cash Per Share | 1.367 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.37 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.74319 |
| Two Hundred Day Average Change | -0.18318999 |
| Two Hundred Day Average Change Percent | -0.24649146 |
| Type Disp | Equity |
| Volume | 455,386 |
| Website | https://www.pasithea.com |
| Zip | 33,139 |